{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:34:16Z","timestamp":1794378856456,"version":"4.9.0"},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,10,10]]},"abstract":"<jats:sec id=\"ab-joi230108-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Gefapixant represents an emerging therapy for patients with refractory or unexplained chronic cough.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi230108-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and tolerability of gefapixant for the treatment of adults with refractory or unexplained chronic cough.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi230108-6\">\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science from November 2014 to July 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi230108-7\">\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Two reviewers independently screened for parallel and crossover randomized clinical trials (RCTs) that compared, in patients with refractory or unexplained chronic cough, either gefapixant with placebo, or 2 or more doses of gefapixant with or without placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi230108-8\">\n                    <jats:title>Data Extraction and Synthesis<\/jats:title>\n                    <jats:p>Two reviewers independently extracted data. A frequentist random-effects dose-response meta-analysis or pairwise meta-analysis was used for each outcome. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach was used to rate the certainty in whether patients would perceive the effects as important (greater than the minimal important difference [MID]) or small (less than the MID).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi230108-9\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Cough frequency (measured using the VitaloJAK cough monitor; MID, 20%), cough severity (measured using the 100-mm visual analog scale [VAS]; higher score is worse; MID, 30 mm), cough-specific quality of life (measured using the Leicester Cough Questionnaire [LCQ]; score range, 3 [maximal impairment] to 21 [no impairment]; MID, 1.3 points), treatment-related adverse events, adverse events leading to discontinuation, and taste-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi230108-10\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine RCTs including 2980 patients were included in the primary analysis. Compared with placebo, gefapixant (45 mg twice daily) had small effects on awake cough frequency (17.6% reduction [95% CI, 10.6%-24.0%], moderate certainty), cough severity on the 100-mm VAS (mean difference, \u22126.2 mm [95% CI, \u22124.1 to \u22128.4]; high certainty), and cough-specific quality of life on the LCQ (mean difference, 1.0 points [95% CI, 0.7-1.4]; moderate certainty). Compared with placebo, gefapixant (45 mg twice daily) probably caused an important increase in treatment-related adverse events (32 more per 100 patients [95% CI, 13-64 more], moderate certainty) and taste-related adverse events (32 more per 100 patients [95% CI, 22-46 more], high certainty). High-certainty evidence suggests that gefapixant (15 mg twice daily) had small effects on taste-related adverse events (6 more per 100 patients [95% CI, 5-8 more]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi230108-11\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Compared with placebo, gefapixant (45 mg orally twice daily) led to modest improvements in cough frequency, cough severity, and cough-specific quality of life but increased taste-related adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2023.18035","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T07:30:43Z","timestamp":1694417443000},"page":"1359","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough"],"prefix":"10.1001","volume":"330","author":[{"given":"Elena","family":"Kum","sequence":"first","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermin","family":"Diab","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafaa","family":"Wahab","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek K.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"O\u2019Byrne","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"},{"name":"Firestone Institute for Respiratory Health, St Joseph\u2019s Healthcare, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon H.","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Satia","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"},{"name":"Firestone Institute for Respiratory Health, St Joseph\u2019s Healthcare, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"joi230108r1","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1183\/09031936.00218714","article-title":"The global epidemiology of chronic cough in adults: a systematic review and meta-analysis.","volume":"45","author":"Song","year":"2015","journal-title":"Eur Respedr J"},{"issue":"15","key":"joi230108r2","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/archinte.158.15.1657","article-title":"Impact of chronic cough on quality of life.","volume":"158","author":"French","year":"1998","journal-title":"Arch Intern Med"},{"issue":"1","key":"joi230108r3","doi-asserted-by":"publisher","first-page":"1S","DOI":"10.1378\/chest.129.1_suppl.1S","article-title":"Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines.","volume":"129","author":"Irwin","year":"2006","journal-title":"Chest"},{"issue":"2","key":"joi230108r4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00408-021-00437-7","article-title":"Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-receptor antagonist gefapixant.","volume":"199","author":"Morice","year":"2021","journal-title":"Lung"},{"issue":"1","key":"joi230108r5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1378\/chest.15-0164","article-title":"Assessment of intervention fidelity and recommendations for researchers conducting studies on the diagnosis and treatment of chronic cough in the adult: CHEST guideline and expert panel report.","volume":"148","author":"French","year":"2015","journal-title":"Chest"},{"issue":"1","key":"joi230108r6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.","volume":"55","author":"Morice","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"joi230108r7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1378\/chest.15-1496","article-title":"Treatment of unexplained chronic cough: CHEST guideline and expert panel report.","volume":"149","author":"Gibson","year":"2016","journal-title":"Chest"},{"issue":"4","key":"joi230108r8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1164\/rccm.200607-892OC","article-title":"Opiate therapy in chronic cough.","volume":"175","author":"Morice","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"9853","key":"joi230108r9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","article-title":"Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial.","volume":"380","author":"Ryan","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"joi230108r10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1378\/chest.15-1271","article-title":"Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial.","volume":"149","author":"Vertigan","year":"2016","journal-title":"Chest"},{"issue":"12","key":"joi230108r11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1097\/01.mlg.0000244377.60334.e3","article-title":"Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy.","volume":"116","author":"Jeyakumar","year":"2006","journal-title":"Laryngoscope"},{"issue":"9974","key":"joi230108r12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","article-title":"P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.","volume":"385","author":"Abdulqawi","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"joi230108r13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00725-2021","article-title":"Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough.","volume":"59","author":"Niimi","year":"2022","journal-title":"Eur Respir J"},{"issue":"5","key":"joi230108r14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04240-2020","article-title":"Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.","volume":"58","author":"Morice","year":"2021","journal-title":"Eur Respir J"},{"issue":"pt 1","key":"joi230108r15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1113\/jphysiol.1996.sp021142","article-title":"Mechanism of action of ATP on canine pulmonary vagal C fibre nerve terminals.","volume":"490","author":"Pelleg","year":"1996","journal-title":"J Physiol"},{"issue":"5","key":"joi230108r16","doi-asserted-by":"publisher","first-page":"L858","DOI":"10.1152\/ajplung.90360.2008","article-title":"P2X2 receptors differentiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs and esophagus.","volume":"295","author":"Kwong","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"pt 3","key":"joi230108r17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1113\/jphysiol.2003.060079","article-title":"Subtypes of vagal afferent C-fibres in guinea-pig lungs.","volume":"556","author":"Undem","year":"2004","journal-title":"J Physiol"},{"key":"joi230108r18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pupt.2019.03.007","article-title":"BLU-5937: a selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.","volume":"56","author":"Garceau","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"issue":"10328","key":"joi230108r19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","article-title":"Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.","volume":"399","author":"McGarvey","year":"2022","journal-title":"Lancet"},{"issue":"71","key":"joi230108r20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"joi230108r21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00408-023-00621-x","article-title":"Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study.","volume":"201","author":"Dicpinigaitis","year":"2023","journal-title":"Lung"},{"issue":"1","key":"joi230108r22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","article-title":"A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough.","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"issue":"2","key":"joi230108r23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04271-2020","article-title":"Performance of a digital signal processing algorithm for the accurate quantification of cough frequency.","volume":"58","author":"Smith","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"joi230108r24","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1378\/chest.14-2506","article-title":"Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report.","volume":"147","author":"Boulet","year":"2015","journal-title":"Chest"},{"issue":"4","key":"joi230108r25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ).","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"issue":"4","key":"joi230108r26","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1378\/chest.121.4.1123","article-title":"Evaluation of a cough-specific quality-of-life questionnaire.","volume":"121","author":"French","year":"2002","journal-title":"Chest"},{"key":"joi230108r27","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"joi230108r28","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/oxfordjournals.aje.a116237","article-title":"Methods for trend estimation from summarized dose-response data, with applications to meta-analysis.","volume":"135","author":"Greenland","year":"1992","journal-title":"Am J Epidemiol"},{"issue":"1","key":"joi230108r29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1536867X0600600103","article-title":"Generalized least squares for trend estimation of summarized dose\u2013response data.","volume":"6","author":"Orsini","year":"2006","journal-title":"Stata J"},{"issue":"5","key":"joi230108r30","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose-response meta-analysis for aggregated data.","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"29","key":"joi230108r31","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1002\/sim.3427","article-title":"Meta-analysis of skewed data: combining results reported on log-transformed or raw scales.","volume":"27","author":"Higgins","year":"2008","journal-title":"Stat Med"},{"issue":"3","key":"joi230108r32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jrsm.v2.3","article-title":"Pooling health-related quality of life outcomes in meta-analysis\u2014a tutorial and review of methods for enhancing interpretability.","volume":"2","author":"Thorlund","year":"2011","journal-title":"Res Synth Methods"},{"issue":"6","key":"joi230108r33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00408-022-00587-2","article-title":"Validation and meaningful change thresholds for an objective cough frequency measurement in chronic cough.","volume":"200","author":"Schelfhout","year":"2022","journal-title":"Lung"},{"key":"joi230108r34","doi-asserted-by":"publisher","DOI":"10.1177\/17534666211049743","article-title":"Validation of a visual analog scale for assessing cough severity in patients with chronic cough.","volume":"15","author":"Martin Nguyen","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"joi230108r35","doi-asserted-by":"publisher","DOI":"10.1177\/17534666221099737","article-title":"Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough.","volume":"16","author":"Nguyen","year":"2022","journal-title":"Ther Adv Respir Dis"},{"issue":"25","key":"joi230108r36","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1002\/sim.4298","article-title":"Expressing findings from meta-analyses of continuous outcomes in terms of risks.","volume":"30","author":"Anzures-Cabrera","year":"2011","journal-title":"Stat Med"},{"issue":"7650","key":"joi230108r38","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"joi230108r39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00439-2019","article-title":"The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.","volume":"54","author":"Morice","year":"2019","journal-title":"Eur Respir J"},{"issue":"3","key":"joi230108r40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01615-2019","article-title":"Gefapixant in two randomised dose-escalation studies in chronic cough.","volume":"55","author":"Smith","year":"2020","journal-title":"Eur Respir J"},{"issue":"8","key":"joi230108r41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","article-title":"Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.","volume":"8","author":"Smith","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"4","key":"joi230108r42","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.alit.2022.05.006","article-title":"A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.","volume":"71","author":"Niimi","year":"2022","journal-title":"Allergol Int"},{"issue":"2","key":"joi230108r43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00408-023-00606-w","article-title":"The efficacy and safety of gefapixant in a phase 3b trial of patients with recent-onset chronic cough.","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"issue":"7472","key":"joi230108r46","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/bmj.329.7472.966","article-title":"Individual response to treatment: is it a valid assumption?","volume":"329","author":"Senn","year":"2004","journal-title":"BMJ"},{"issue":"1","key":"joi230108r47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2288-7-30","article-title":"The Hawthorne effect: a randomised, controlled trial.","volume":"7","author":"McCarney","year":"2007","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"joi230108r48","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.21037\/jtd","article-title":"A neuroanatomical framework for the central modulation of respiratory sensory processing and cough by the periaqueductal grey.","volume":"9","author":"McGovern","year":"2017","journal-title":"J Thorac Dis"},{"issue":"9","key":"joi230108r49","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1164\/rccm.201306-1079OC","article-title":"Brain activity associated with placebo suppression of the urge-to-cough in humans.","volume":"188","author":"Leech","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"joi230108r50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01387-2020","article-title":"The effect of pain conditioning on experimentally evoked cough: evidence of impaired endogenous inhibitory control mechanisms in refractory chronic cough.","volume":"56","author":"Hilton","year":"2020","journal-title":"Eur Respir J"},{"issue":"11","key":"joi230108r51","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1164\/rccm.202211-2128LE","article-title":"Efficacy and safety of gefapixant for refractory or unexplained chronic cough over 52 weeks.","volume":"207","author":"Birring","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"joi230108r37","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"joi230108r44","unstructured":"An 8-week refractory chronic cough study (MK-7264-021) [NCT02612623]. ClinicalTrials.gov. 2015. Accessed August 29, 2023. http:\/\/ClinicalTrials.gov\/study\/NCT02612623"},{"key":"joi230108r45","unstructured":"Study of gefapixant (MK-7264) in adult Japanese participants with unexplained or refractory chronic cough (MK-7264-033) [NCT03482713]. ClinicalTrials.gov. 2018. Accessed August 29, 2023. http:\/\/ClinicalTrials.gov\/study\/NCT03482713"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2809599\/jama_kum_2023_oi_230108_1696345497.21178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T11:07:34Z","timestamp":1696936054000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2809599"}},"subtitle":["A Systematic Review and Dose-Response Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":51,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,10,10]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.18035","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,10]]}}}